CIA
ATRA icon

Capital Impact Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Capital Impact Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-560
Closed -$199K – 167
2016
Q4 		$199K Hold
560
– – 0.08% 213
2016
Q3 		$299K Buy
+560
New +$304K 0.13% 213

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Impact Advisors's ATRA Position: Q1 2017 in Review

Capital Impact Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2017, closing a stake of 560 shares — an estimated $199K sold.

Capital Impact Advisors first reported a position in ATRA in Q3 2016 and held it in 2 quarters. The position peaked at $299K in Q3 2016. 85 funds tracked by Wall St. Rank hold ATRA as of Q1 2017.

  • Capital Impact Advisors reported no remaining Atara Biotherapeutics position as of Q1 2017 after selling out during the quarter.
  • Capital Impact Advisors sold 560 Atara Biotherapeutics shares in Q1 2017, an estimated $199K.
  • Capital Impact Advisors first reported a position in Atara Biotherapeutics in Q3 2016 and held it in 2 quarters.
  • Capital Impact Advisors's Atara Biotherapeutics position peaked at $299K in Q3 2016.
  • 85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2017.

Based on Capital Impact Advisors's 13F filing for Q1 2017, filed 19 Apr 2017.